Antiplatelet therapy to prevent cardiovascular events and mortality in patients with intermittent claudication

JAMA

Volumn 309, Issue 9, 2013, Pages 926-927

  Wong, Peng Foo ^a   Chong, Lee Yee ^b   Stansby, Gerard ^c  

^a JAMES COOK UNIVERSITY HOSPITAL   (United Kingdom)

^b ROYAL COLLEGE OF PHYSICIANS   (United Kingdom)

^c FREEMAN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; INDOBUFEN; PICOTAMIDE; PLACEBO; TICLOPIDINE; TRIFLUSAL;

BLEEDING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; DIARRHEA; DRUG ERUPTION; DRUG WITHDRAWAL; DYSPEPSIA; EPIGASTRIC PAIN; ERYTHEMA; HEART INFARCTION; HUMAN; INTERMITTENT CLAUDICATION; MORTALITY; NAUSEA; NOTE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; TREATMENT OUTCOME; VOMITING; CAUSE OF DEATH; EVIDENCE BASED MEDICINE; PRACTICE GUIDELINE; REVIEW;

CARDIOVASCULAR DISEASES; CAUSE OF DEATH; EVIDENCE-BASED MEDICINE; HUMANS; INTERMITTENT CLAUDICATION; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

MLCS; MLOWN;

EID: 84874704080     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2013.1490     Document Type: Note

References (9)

1. Alonso-Coello P, Bellmunt S, McGorrian C, et al American College of Chest Physicians. Antithrombotic therapy in peripheral artery disease. Chest . 2012;141(2)(suppl):e669S-e690S.
2. Rooke TW, Hirsch AT, Misra S, et al. 2011 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Peripheral Artery Disease (updating the 2005 guideline). J Am Coll Cardiol. 2011;58(19):2020-2045.
3. Bell AD, Roussin A, Cartier R, et al. The use of antiplatelet therapy in the outpatient setting: Canadian Cardiovascular Society guidelines. Can J Cardiol. 2011;27(suppl A):S1-S59.
4. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg. 2007;33(suppl 1):S1-S75.
5. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71-86.
6. Wong PF, Chong LY, Mikhailidis DP, Robless P, Stansby G. Antiplatelet agents for intermittent claudication. Cochrane Database Syst Rev. 2011;11(11):CD001272. doi:10.1002/14651858.CD001272.pub2.
7. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348(9038):1329-1339.
8. Neri Serneri GG, Coccheri S, Marubini E, et al. Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study. Eur Heart J. 2004;25(20):1845-1852.
9. National Institute for Health and Clinical Excellence. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events. http://publications.nice.org.uk/clopidogrel-and-modified-release-dipyridamole- for-the-prevention-of-occlusive-vascular-events-ta210. Published December 2010. Accessed September 9, 2012.